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The introduction of bevacizumab (Avastin), an antibody 
to the vascular endothelial growth factor (VEGF), into 
the repertoire of the medical management of malignant 
gliomas has influenced the area of glioma treatment 
quite markedly.
First, after decades of aiming at stopping tumor 
growth and being quite satisfied with documenting 
“stable disease,” we are suddenly observing objective 
response rates at a never-seen frequency exceeding 50%.1 
Admittedly, we have not been convinced by any report 
that the high response rate translates into a gain in sur-
vival. The progression-free survival rate at 6 months— 
our current gold standard of assessing novel treatments 
for recurrent glioblastoma—may be in the range of 40%, 
but similar figures are also achieved with dose-intense 
regimens of temozolomide.
Second, we may need to reconsider the MacDonald 
response criteria, which overall have served us well in 
assessing the efficacy of novel treatments, but which are 
heavily based on contrast enhancement. Yet in the era 
of antiangiogenic agents like bevacizumab, which may 
soon be joined by cilengitide or enzastaurin, altered pat-
terns of recurrence resulting from a change from vessel/
VEGF-dependent growth to vessel/VEGF-independent 
tumor growth2 may necessitate the development of new 
response criteria.
Third, and perhaps heralding new patterns of toxic-
ity common to the new class of antiangiogenic agents 
for glioma treatment, the fear of intratumoral hemor-
rhages may not have been justified, but craniotomy site 
dehiscence is increasingly noted as a relevant complica-
tion in a minority of glioma patients treated with beva-
cizumab.3
Fourth, the impressive effects of the combination 
of bevacizumab and irinotecan were unexpected and 
initially suggested strong synergistic potential for two 
agents that appeared to have limited activity when 
administered alone. Yet the results from the first ran-
domized trial of bevacizumab alone versus bevacizumab 
plus irinotecan presented by Cloughesy and colleagues at 
the 2008 American Society for Clinical Oncology meet-
ing in Chicago appear to confirm the suspicion that iri-
notecan is contributing little to the overall effect of this 
novel regimen. Along these lines, switching patients who 
progress under bevacizumab and irinotecan to another 
bevacizumab-containing regimen seems to offer little 
hope for response.2
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In the current issue of Neuro-Oncology, Ingeborg 
Fischer and colleagues report on their investigation into 
histological features of malignant gliomas after treat-
ment with bevacizumab.4 Five paired tissues obtained 
prior to and after exposure to bevacizumab were avail-
able and compared with four paired tissues from patients 
never exposed to bevacizumab. Decreased vessel density 
correlated with radiographic responses to bevacizumab, 
whereas the levels of VEGF-A and various other histo-
logical and immunochemistry parameters did not. While 
the case numbers of this study are low, such tissues are 
difficult to assemble, and approaches as outlined here 
are very important. They are likely to result in the iden-
tification of biomarkers associated with response, or the 
lack thereof, to experimental brain tumor treatments 
and will help to design a scientific basis and possibly 
new endpoints for upcoming clinical trials, notably in 
the emerging field of novel antiangiogenic agents.
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